Your browser doesn't support javascript.
Potential antiviral properties of antiplatelet agents against SARS-CoV-2 infection: an in silico perspective.
Abosheasha, Mohammed A; El-Gowily, Afnan H; Elfiky, Abdo A.
  • Abosheasha MA; Cellular Genetics Laboratory, Graduate School of Science, Tokyo Metropolitan University, Tokyo, Japan.
  • El-Gowily AH; Department of Chemistry, Biochemistry Division, Faculty of Science, Tanta University, Tanta, Egypt.
  • Elfiky AA; Department of Organ and Cell Physiology, Juntendo University, Tokyo, Japan.
J Thromb Thrombolysis ; 53(2): 273-281, 2022 Feb.
Article in English | MEDLINE | ID: covidwho-1401065
ABSTRACT
SARS-CoV-2 represents the causative agent of the current pandemic (COVID-19). The drug repurposing technique is used to search for possible drugs that can bind to SARS-CoV-2 proteins and inhibit viral replication. In this study, the FDA-approved antiplatelets are tested against the main protease and spike proteins of SARS-CoV-2 using in silico methods. Molecular docking and molecular dynamics simulation are used in the current study. The results suggest the effectiveness of vorapaxar, ticagrelor, cilostazol, cangrelor, and prasugrel in binding the main protease (Mpro) of SARS-CoV-2. At the same time, vorapaxar, ticagrelor, and cilostazol are the best binders of the spike protein. Therefore, these compounds could be successful candidates against COVID-19 that need to be tested experimentally.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Platelet Aggregation Inhibitors / SARS-CoV-2 Limits: Humans Language: English Journal: J Thromb Thrombolysis Journal subject: Vascular Diseases Year: 2022 Document Type: Article Affiliation country: S11239-021-02558-5

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Platelet Aggregation Inhibitors / SARS-CoV-2 Limits: Humans Language: English Journal: J Thromb Thrombolysis Journal subject: Vascular Diseases Year: 2022 Document Type: Article Affiliation country: S11239-021-02558-5